CYCCP News and Press, Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock From 12/12/23

BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse ...

2023-12-01 11:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice from The Na...

BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice of non-complianc...

2023-11-13 19:32:06 ET Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President, CEO Paul McBarron - EVP, Finance & COO Mark Kirschbaum - SVP, CMO ...

- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to Host Conference Call at 4:30 pm ET Today - BERKELEY HEIGHTS, N.J., Nov. 13, 202...

BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2023 financial results on Mond...

2023-10-18 11:22:58 ET More on Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Call Transcript Historical earnings data for Cyclacel Pharmaceuticals, Inc. PFD CONV EX 6% Dividend scorecard for Cyclacel Pharmaceutica...

2023-08-09 21:42:12 ET Cyclacel Pharmaceuticals Inc. (CYCC) Q2 2023 Earnings Conference Call Aug 9, 2023 4:30 PM ET Company Participants Grace Kim - Investor Relations Spiro Rombotis - President and Chief Executive Officer Mark Kirschbaum - Senior Vice President ...

- Key Catalysts ahead with Multiple Value Generating Readouts- - Expects to Release Phase 1/2 Data with Oral Fadraciclib - - Signals of Single-agent Efficacy with Oral Plogosertib - - Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGH...